Advertisement

Serum Levels of Soluble TNF-α Receptor-II (P75), Circulating γδ T-Cells and Adamantiades-behçet’s Disease Activity

  • Antonia V. Elezoglou
  • Peter P. Sfikakis
  • George Vaiopoulos
  • Violeta Kapsimali
  • Phaedon G. Kaklamanis
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 528)

Keywords

Systemic Lupus Erythematosus Inactive Disease Genital Ulceration International Study Group Ocular Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yazici, H., 1994, Behçet’s syndrome. In Rheumatology (J.H. Klippel, P.A. Dieppe, eds.), Mosby-Year Book Europe.Google Scholar
  2. 2.
    Sakane, T., Takeno, M., Suzuki, N., et al., 1999, Behçet’s disease. N. Engl. J. Med. 341: 1284–1291.CrossRefPubMedGoogle Scholar
  3. 3.
    Direskeli, H., Eksioglu-Demiralp, E., Kibaroglu, A., et al., 1999, Oligoclonal T cell expansions in Behçet’s disease. Clin. Exp. Immunol. 117: 166–170Google Scholar
  4. 4.
    Yamashita, N., Kaneoka, H., Kaneko, S., et al., 1997, Role of γδ T lymphocytes in the development of Behçet’s disease. Clin. Exp. Immunol. 107: 241–247.CrossRefPubMedGoogle Scholar
  5. 5.
    Hart, P.H., Hunt E.K., Bonder, C.S., et al., 1996, Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophage by IL-4 and IL-10. J. Immunol. 157: 3672–3680.PubMedGoogle Scholar
  6. 6.
    Cope, A.P., and Maini, R.N., 1995, Soluble TNF receptors in arthritis. J. Rheumatol. 22: 382–384.PubMedGoogle Scholar
  7. 7.
    Weckmann, A.L., and Alcocer-Verela, J., 1996, Cytokine inhibitors in autoimmune disease. Semin. Arthritis Rheum. 26: 539–557.CrossRefPubMedGoogle Scholar
  8. 8.
    Sayinalp, N., Ozcebe, O.I., Ozdemir, O., et al., 1996, Cytokines in Behçet’s disease. J. Rheumatol. 23: 321–322.PubMedGoogle Scholar
  9. 9.
    Turan, B., Gallati, H., Erdi, H., et al., 1997, Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet’s disease; soluble TNFR-75 as a biological marker of disease activity. J. Rheumatol. 24: 128–132.PubMedGoogle Scholar
  10. 10.
    International Study Group for Behçet’s Disease, 1990, Criteria for diagnosis of Behçet’s Disease. Lancet 335: 1078–1080.Google Scholar
  11. 11.
    Sfikakis, P.P., Theodosiades, P.G., Katsiari, C.G., et al., 2001, Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358: 295–296.CrossRefPubMedGoogle Scholar
  12. 12.
    Katsiari, C.G., Liossis, S.-N.C., Souliotis, V.L., et al., 2002, Aberrant expression of the costimulatory molecule CD40L on monocytes from patients with systemic lupus erythematosus. Clin. Immunol. 103: 54–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Gabay, C., Cakir, N., Moral, F., et al., 1997, Circulating levels of TNF soluble receptors in SLE are significantly higher than in other rheumatic diseases and correlate with disease activity. J. Rheumatol. 24: 303–308.PubMedGoogle Scholar
  14. 14.
    Heilig, B., Fiehn, C., Brockhaus, M., et al., 1993, Evaluation of soluble TNF receptors in patients with SLE, PSS and MCTD. J. Clin. Immunol. 13: 321–328.CrossRefPubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Antonia V. Elezoglou
    • 2
  • Peter P. Sfikakis
    • 2
  • George Vaiopoulos
    • 3
  • Violeta Kapsimali
    • 1
  • Phaedon G. Kaklamanis
    • 3
  1. 1.Immunology DepartmentEvagelismos HospitalAthensGreece
  2. 2.First Dept of Propedeutic Medicine Laikon HospitalAthens University Medical SchoolAthensGreece
  3. 3.First Department of Medicine, Laikon HospitalAthens University Medical SchoolAthensGreece

Personalised recommendations